Factor XII deficiency: A thrombophilic risk factor for retinal vein occlusion

• Published in: American journal of ophthalmology 2004-03, Vol.137 (3), p.459-464
• Main Authors: Kuhli, Claudia, Scharrer, Inge, Koch, Frank, Ohrloff, Christian, Hattenbach, Lars-Olof
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antigens; Biological and medical sciences; Blood pressure; Cardiovascular Diseases - epidemiology; Cross-Sectional Studies; Diabetes; Disease; Factor XII - analysis; Factor XII Deficiency - epidemiology; Family medical history; Female; Health risk assessment; Hematologic and hematopoietic diseases; Humans; Hypertension; Male; Medical sciences; Middle Aged; Patients; Plasma; Platelet diseases and coagulopathies; Prevalence; Prospective Studies; Retinal Vein Occlusion - diagnosis; Retinal Vein Occlusion - epidemiology; Risk Factors; Studies; Thrombophilia - epidemiology; Thrombosis; Veins & arteries
• ISSN: 0002-9394; 1879-1891
• DOI: 10.1016/j.ajo.2003.10.024

Factor XII deficiency is among the coagulation disorders that have been implicated in major thromboembolic events. However, little is known about an association of this coagulation disorder and retinal vessel occlusion. In the current study, we investigated the prevalence of factor XII deficiency in patients with retinal vein occlusion (RVO) with reference to age and cardiovascular risk factors. Cross-sectional study. A cohort of 150 consecutive patients with central or branch retinal vein occlusion and 135 subjects matched for age and gender were prospectively screened for factor XII deficiency. Both cohorts were divided into two subgroups (≤45 or >45 years), depending on the patients' age at the time of the RVO or a previous thromboembolic event. Overall, factor XII deficiency was found to be present in 14 (9.3%) of 150 patients and in 1 (0.7%) of 135 controls (P = .0009). Patient age ≤45 years at the time of the RVO or a previous thromboembolic event was associated with a high prevalence of factor XII deficiency (18%). By contrast, only 5 (5%) of 100 patients >45 years (P = .016) and none of the young controls (P = .0001) tested positive for factor XII deficiency. The prevalence among patients >45 years was similar to that found in age-matched controls (2%; P = .66). Our results indicate that factor XII deficiency is highly prevalent in RVO patients ≤45 years of age. By contrast, the prevalence of factor XII deficiency in RVO patients older than 45 years appears to be similar to that seen in healthy individuals.